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Cell polarity factor Par3 binds SPTLC1 and modulates monocyte
serine palmitoyltransferase activity and chemotaxis
Abstract
Elevated sphingolipids have been associated with increased cardiovascular disease. Conversely,
atherosclerosis is reduced in mice by blocking de novo synthesis of sphingolipids catalyzed by serine
palmitoyltransferase (SPT). The SPT enzyme is composed of the SPTLC1 and -2 subunits, and here we
describe a novel protein-protein interaction between SPTLC1 and the PDZ protein Par3 (partitioning
defective protein 3). Mammalian SPTLC1 orthologs have a highly conserved C terminus that conforms
to a type II PDZ protein interaction motif, and by screening PDZ domain protein arrays with an SPTLC1
C-terminal peptide, we found it bound the third PDZ domain of Par3. Overlay and immunoprecipitation
assays confirmed this interaction and indicate Par3 is able to associate with the SPTLC1/2 holoenzyme
by binding the C-terminal SPTLC1 PDZ motif. The physiologic existence of the SPTLC1/2-Par3
complex was detected in mouse liver and macrophages, and short interfering RNA inhibition of Par3 in
human THP-1 monocytes significantly reduced SPT activity and de novo ceramide synthesis by nearly
40%. Given monocyte recruitment into inflamed vessels is thought to promote atherosclerosis, and
because Par3 and sphingolipids have been associated with polarized cell migration, we tested whether
the ability of THP-1 monocytes to migrate toward MCP-1 (monocyte chemoattractant protein 1)
depended upon Par3 and SPTLC1 expression. Knockdown of Par3 significantly reduced MCP1-induced
chemotaxis of THP-1 monocytes, as did knockdown of SPTLC1, and this Par3 effect depended upon
SPT activity and was blunted by ceramide treatment. In conclusion, protein arrays were used to identify
a novel SPTLC1-Par3 interaction that associates with increased monocyte serine palmitoyltransferase
activity and chemotaxis toward inflammatory signals.
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Elevated sphingolipids have been associated 
with increased cardiovascular disease. 
Conversely, atherosclerosis is reduced in mice 
by blocking de novo synthesis of sphingolipids 
catalyzed by serine palmitoyltransferase 
(SPT). The SPT enzyme is composed of the 
SPTLC1 and 2 subunits, and here we describe 
a novel protein-protein interaction between 
SPTLC1 and the PDZ protein Partitioning 
defective protein 3 (Par3). Mammalian 
SPTLC1 orthologs have a highly conserved C-
terminus that conforms to a type II PDZ 
protein interaction motif, and by screening 
PDZ domain protein arrays with a SPTLC1 C-
terminal peptide we found it bound the 3rd 
PDZ domain of Par3. Overlay and immuno-
precipitation assays confirmed this interaction 
and indicate Par3 is able to associate with the 
SPTLC1/2 holoenzyme by binding the C-
terminal SPTLC1 PDZ motif. The physiologic 
existence of the SPTLC1/2-Par3 complex was 
detected in mouse liver and macrophages, and 
siRNA inhibition of Par3 in human THP-1 
monocytes significantly reduced SPT activity 
and de novo ceramide synthesis by nearly 
40%. Given monocyte recruitment into 
inflamed vessels is thought to promote 
atherosclerosis, and since Par3 and 
sphingolipids have been associated with 
polarized cell migration, we tested whether the 
ability of THP-1 monocytes to migrate 
towards monocyte chemoattractant protein 1 
(MCP-1) depended upon Par3 and SPTLC1 
expression. Knockdown of Par3 significantly 
reduced MCP1 induced chemotaxis of THP-1 
monocytes, as did knockdown of SPTLC1, 
and this Par3 effect depended upon SPT 
activity and was blunted by ceramide 
treatment. In conclusion, protein arrays were 
used to identify a novel SPTLC1-Par3 
interaction that associates with increased 
monocyte serine palmitoyl-transferase 
activity and chemotaxis towards 
inflammatory signals.  
 
Sphingolipids are a structurally diverse 
lipid class that are important for membrane 
structure, cell proliferation, immune function 
and skin physiology (1-4). De novo sphingolipid 
synthesis is initiated by serine 
palmitoyltransferase (SPT), an enzyme that 
condenses serine and palmitoyl-CoA forming 
the biosynthetic intermediate 3-
ketodihydosphingosine that is subsequently 
converted to ceramide, sphingomyelin and other 
sphingolipids (5). SPT is a heterodimer 
composed of the SPTLC1 & 2 subunits (6,7), 
which may form higher order multimeric 
structures that can include a third subunit, 
SPTLC3 (8,9). Both the SPTLC2 and 3 subunits 
are catalytically active and contain conserved 
lysines that act as Schiff’s bases during the 
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condensation reaction (5,8). In contrast, SPTLC1 
does not contain the conserved catalytically 
active lysine, but is important for stabilizing the 
SPTLC2 subunit and anchoring the SPT 
holoenyzme on the cytosolic face of the 
endoplasmic reticulum (10,11).  
 
Expression and regulation of the SPTLC1/2 
holoenyzme is of interest since its activity 
controls de novo synthesis of sphingomyelin, and 
increased plasma levels of this sphingolipid have 
been correlated with an increased incidence of 
cardiovascular disease in humans (12,13). 
Conversely, inhibition of SPT activity with 
myriocin, a fungal metabolite, strongly inhibits 
atherosclerotic development in ApoE-/- mice (14-
18). Moreover, the increased atherosclerosis seen 
in ApoE-/- mice has been associated with a post-
translational increase in liver SPT activity (19). 
How SPT activity and sphingolipids may act to 
promote the progression of atherosclerosis is 
unclear, but this data does suggest analysis of 
factors that regulate SPT activity should provide 
mechanistic insight into the link between de novo 
sphingolipid synthesis and atherosclerosis. In this 
regard we have found that SPTLC1 can interact 
with the ABCA1 transporter and inhibit its ability 
to transfer cholesterol to apoA-I, a mechanism 
that would be expected to promote 
atherosclerosis (20). Thus, along with playing a 
direct role in the synthesis of sphingolipids, 
SPTLC1 may also have evolved as a SPT subunit 
whose function it is to regulate SPT activity in 
response to the cellular demand for sphingolipids 
and other membrane constituents such as 
cholesterol. To play such a role, SPTLC1 may 
engage additional protein-protein interactions that 
integrate input from signaling pathways and 
allow SPTLC1 to modulate SPT activity in 
response to altered demand for sphingolipids.  
 
Here we have explored this hypothesis by first 
conducting a protein array screen for SPTLC1 
interacting factors. Consistent with the potential 
to engage cellular factors in protein-protein 
interactions, sequence alignment of the SPLTC1 
C-terminus indicates it has been strongly 
conserved in mammals as a type II PDZ domain 
binding motif. Moreover, since topology studies 
indicate the SPTLC1 C-terminus resides in the 
cytoplasm where it could be bound by PDZ 
proteins, we used protein arrays spotted with 
123 PDZ domains from 73 different proteins to 
screen for interactions with the SPTLC1 C-
terminus. This screen indicated the SPTLC1 C-
terminus directly interacts with the 3rd PDZ 
domain of Partitioning Defective Protein 3 
(PARD3). PARD3, also known as Par3, is a 
scaffolding factor that recruits signaling 
molecules including atypical protein kinase C 
and Cdc42 into multiprotein complexes that 
regulate formation of membrane microdomains 
required for apical/basal polarity and for 
directed cell migration (21-25). Mutation 
analysis confirmed the SPTLC1-Par3 interaction 
depended upon the SPTLC1 C-terminal PDZ 
motif, and immunoprecipitation assays indicate 
Par3 is able to associate with the SPTLC1/2 
holoenyzme by binding the SPTLC1 C-terminal 
PDZ motif. The Par-3 interaction with the 
SPTLC1/2 holoenyzme was detected in the liver, 
a major site of SPT activity and sphingolipid 
synthesis. Given SPT activity is 
proatheroslerotic, and since we have also 
detected SPTLC1 expression in macrophages, a 
cell type that plays a central role in the 
progression of atherosclerosis, we tested and 
found that Par3 was expressed and interacted 
with the SPT holoenyzme in primary mouse 
macrophages. Significantly, loss of Par3 
expression in human THP-1 monocyte 
macrophages reduced SPT activity and inhibited 
their ability to migrate towards monocyte 
chemotactic protein-1 (MCP-1). Likewise, 
shRNA suppression of SPTLC1 reduced 
monocyte migration towards MCP-1, as did 
myriocin inhibition of SPT activity, an effect 
that was blunted by loss of Par3 expression. In 
aggregate, our work has identified a novel 
protein-protein interaction between SPTLC1 and 
Par3 that is associated with an increase in SPT 
activity and the promotion of polarized cell 
migration in response to an inflammatory signal.  
 
Experimental Procedures 
Reagents, Cells and DNA constructs – The 
following reagents were purchased from the 
indicated suppliers: Human Poly A+ mRNA 
tissue blot (Origene); myriocin and C16-ceramide 
(Biomol), anti-Par3 antibody (Upstate), anti-HA 
and Myc tag antibodies (Covance). The 
SPTLC1, SPTLC2 and SPTLC3 antibodies have 
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been previously described (8,9). The LY-B cell 
line was obtained from Dr. Kentaro Hanada via 
the RIKEN BRC cell bank. The human THP-1 
monocyte and 293HEK cell lines were obtained 
from the American Type Culture Collection. 
Primary bone marrow derived macrophages were 
obtained from C57/BL6 mice and cultured as 
previously described (20). Plasmids containing 
the cDNAs for SPTLC1, SPTLC-2 and the 150 
kDa isoform of Par-3 were obtained from Open 
BioSystems and Dr. Ramnik Xavier of the CCIB, 
respectively. Integrity of the cDNA open reading 
frames were confirmed by sequencing, and as 
needed the cDNAs were modified to generate N-
terminally FLAG (FL), Hemagglutin (HA), and 
Myc tagged versions of the encoded proteins 
using standard cloning techniques. 
 
SPTLC1, 2 and 3 Ortholog alignments: The 
Ensembl genome database was used to align the 
orthologs of SPTLC1, SPTLC2 and SPTLC3 
(26). The SPTLC1 C-terminal residues in all 17 
sequenced placental mammalian genomes were 
found to be conserved as a type II PDZ motif 
characterized by hydrophobic residues at 
positions 0 and –2 (X-Φ-2-X-1-Φ0-COOH). In 
SPTLC1 orthologs from other phyla these 
sequences were more variable and did not 
conform to a known PDZ binding motif with the 
exception of SPTLC1 from Gasterosteus 
aculeatus and Drosophila melanogaster. 
Alignments of the SPTLC2 and SPTLC3 
orthologs showed these subunits have been 
conserved but that their C-termini do not conform 
to any known PDZ binding motifs.  
 
PDZ array screen and overlay assays– To screen 
for C-terminal SPTLC1 protein-protein 
interactions we synthesized a N-terminally 
biotinylated SPTLC1 peptide (Biotin- 
EEELQRAASTIREAAQAVLL-COOH). The 
peptide was purified to greater >95% 
homogeneity using high-pressure liquid 
chromatography as determined by mass 
spectrometry. The peptide was incubated with 
protein arrays spotted in duplicate with 123 PDZ 
domains from 73 PDZ domain-containing 
proteins (150 nM in blocking buffer, Panomics). 
After washing, peptide binding was detected 
using an HRP-avidine conjugate and enhanced 
chemiluminescence. Arrays were imaged and 
quantified using an Alpha Innotech FluorChem 
8800 instrument as previously described (27). 
The binding of full-length Par3 protein (150 kDa 
isoform) to the SPTLC1 C-terminus was 
determined using overlay assays as previously 
described (28). In brief, sequences representing 
the C-terminal 75 amino acids of SPTLC1 were 
expressed and purified from bacteria as His-
tagged polypeptides with or without an intact 
PDZ motif (wild-type, Δ3, VLL-AAA). The 
polypeptides were separated by SDS-PAGE, 
transferred to nitrocellulose, and incubated with 
a lysate from 293-EBNA-T cells expressing full-
length HA-tagged Par3. After washing the blot 
(1X PBS, 0.1% Tween-20), the binding of Par3 
was detected using the anti-HA antibody. The 
coomassie staining of gels run in parallel was 
used to demonstrate the equal loading of His-
tagged SPTLC1 polypeptides. 
 
Immunological, RNA and shRNA methods – To 
assess the tissue distribution of the Par3 protein, 
lysates (1% Trinton X-100, 10% glycerol, 
140mM NaCl, 3mM MgCl2, 50mM HEPES, pH 
7.4, protease inhibitor cocktail, Sigma) were 
generated from the indicated mouse C57/BL6 
tissues and the samples (20 ug total protein) 
were separated by SDS-PAGE. After transfer to 
nitrocellulose membranes, Par3 expression in 
the samples was detected by immunoblotting 
with the anti-Par3 antibody, and to test for 
SPTLC1 expression the blot was stripped and re-
probed with the anti-SPTLC1 antibody. To 
assess the tissue distribution of Par3 mRNA 
versus that of FRMPD4 mRNA, a human 
mRNA tissue blot (Origene) was sequentially 
probed with radio-labeled DNA derived from 
the cDNAs for Par3, FRMPD4 and β-actin. 
Images of the resulting Northern blots were 
captured and quantified using a Typhoon 
phosphor imager (GE Healthcare). To analyze 
the role that the SPTLC1 PDZ motif plays in 
allowing Par3 to associate with the SPTLC1/2 
holoenzyme, Flag-SPTLC1 and the indicated 
FL-SPTLC1 C-terminal PDZ motif mutants 
were expressed in 293-EBNA-T cells in the 
presence of HA-Par3 and Myc-SPTLC2 using 
transient transfection methods (Lipofectamine 
2000, Invitrogen). 36h post-transfection triton-
X-100 lysates were prepared and 0.5 mg of the 
lysates was precipitated with 35ul of anti-FLAG 
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antibody beads (Sigma), anti-HA-antibody or 
anti-Myc antibody as indicated in the specific 
experiments. After washing and elution of the 
precipitated proteins the amount of Par3, 
SPTLC1 and SPTLC2 was determined by 
immunoblotting using the appropriate primary 
antibodies and a secondary TrueBlot antibody 
(eBiosciences). Immuno-precipitation assay using 
mouse liver and bone marrow derived 
macrophages lysate were carried out as above 
using anti-SPTLC1 and SPTLC2 antibodies and 
TrueBlot anti-rabbit IgG beads (eBiosciences). 
For shRNA knockdown of Par3, primary 
screening of OpenBiosystems lentiviral 
constructs targeting human Par3 showed clones 
NM_019619.2-2017s1c1 and NM_019619.2-
2782s1c1 (denoted F12 and G1 in the figures) 
had the greatest efficacy to reduce expression of 
the Par3 protein as assessed by transient 
transfection of the human Par3 cDNA with these 
clones. Particles generated by packaging these 
lentiviral constructs were used to infect THP-1 
monocytes and stable clones expressing the 
shRNAs targeting Par3 were obtained by 
selection with puromycin (4 µg/ml, 48 h post-
infection for 72 h). Likewise, THP-1 cells 
expressing the shRNA targeting SPTLC1 or a 
control shRNA targeting green fluorescent 
protein (GFP) were also generated by puromycin 
selection as previously described (20).  
 
Cell migration assay – To the measure the 
importance of Par3 and SPTLC1 for THP-1 
monocyte migration cells were suspended in 
RPMI 1640 (0.1% BSA) at 2 x 106 cells/ml. 50 ul 
of the cell suspensions were transferred to the 
upper wells of a ChemoTx 96 well assay plate 
with a 8 μm pore filter (Neuroprobe). The lower 
chamber contained 30 μl of media with or 
without 10nM MCP-1, Fractalkine or fMLP 
(R&D systems). The plates were incubated at 37° 
for 2 h, and after washing the filter with PBS, the 
plates were spun at 400 x g for 5 min. Cells that 
had migrated into the lower camber were 
subsequently quantitated using the Cell titer-Glo 
assay (Promega). Additional assays for viability 
were conducted using the MTT assay as 
previously described (20). 
 
Serine palmitoyltransferase activity – THP-1 
cells were harvested by centrifugation (5 min, 
900x g), lysed in a hypotonic buffer (250 mM 
sucrose, 10 mM HEPES pH 7.5, protease 
inhibitor cocktail), cell debris was removed by 
centrifugation (10 min, 900 x g) and a 
microsome membrane fraction was obtained by 
centrifugation (1 h, 100,000 x g). The resulting 
membrane pellet was re-suspended in reaction 
buffer (50 mM HEPES buffer, pH 8.0, 0.5 mM 
L-serine, 50 uM palmitoyl-CoA, 20 uM 
pyridoxial 5’-phosphate) with 1 uCi L-
[14C]serine at 0.2 mg of microsomal protein/ 0.2 
ml reaction buffer. After incubation for 20 min 
at 37° C, the reaction was stopped by adding 0.5 
ml of 100 mM KOH in methanol/chloroform 
(4:1), followed by addition of 0.5 ml of 
chloroform. Then 0.5 ml of 2mM ammonium 
and 0.1 ml of 2 N NH4OH were added, the 
reaction was vortexed and then centrifuged. The 
resulting upper aqueous layer was aspirated, and 
lower organic phase was washed two times with 
0.9 ml of 0.002 N ammonium hydroxide. 400ul 
of the resulting organic phase was mixed with 
scintillation fluid and the amount of L-
[14C]serine containing lipids was quantified 
using a Brinkman scintillation counter. 
 
Metabolic labeling of cellular sphingolipids – 
To measure de novo sphingolipid synthesis, 
THP-1 cells (5 x 106 cells) were suspended in 
RPMI medium (10% fetal bovine serum). The 
cells were either pretreated with vehicle or 10 
μM myriocin (Biomol) for 2 hr and then were 
labeled with 5 μCi/ml of 14C-serine for 24 h at 
37º C. Cells were harvested by centrifugation, 
washed with 1X PBS, and lipids were extracted 
1X with 0.75 ml of chloroform/methanol (1:2 
v/v) and 1X with 0.25 ml chloroform/0.2 ml 
dH20. After centrifugation the combined organic 
layer was washed and dried under a stream of 
nitrogen gas. The samples were resuspended in 
chloroform/methanol (1:2 v/v) and applied to 10 
x 16 cm thin-layer Silicagel 60F plates (Merck). 
The plates were developed sequentially with 
chloroform/methanol/water (14/6/1,v/v/v) and 
chloroform/methanol/acetic acid (190/9/1, v/v/v) 
as previously described (29). Radioactivity was 
quantified using a Typhoon phosphor imager 
(GE Healthcare). 
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Statistical Analysis- Data sets were found to have 
equal variance and were further compared by a 
two-tailed Student’s T test using the SigmaStat 
software package. Statistical significance was 
defined by a p value < 0.05. 
 
RESULTS 
SPTLC1 is bound by Par3 through a type II PDZ 
protein interaction: SPT activity in mammalian 
cells localizes to the cytosolic face of the 
endoplasmic reticulum and topology studies have 
shown that mammalian SPTLC1 contains a single 
transmembrane domain and a cytoplasmic C-
terminus (10,11,30). Given the orientation of the 
C-terminus this domain may allow SPTLC1 to 
interact with cytoplasmic proteins. PDZ proteins 
are cytoplasmic factors that contain one or more 
90 amino acid modules that bind the C-termini of 
other proteins, and this capacity along with 
additional protein-binding domains allows PDZ 
proteins to assemble signaling and membrane 
microdomain complexes. Ortholog alignment of a 
protein’s C-terminal residues can predict its 
potential to interact with PDZ domains (31,32), 
thus using the Ensembl database we aligned 
SPTLC1 orthologs from a variety of species (Fig. 
1A). This showed the SPTLC1 C-terminus to 
have been strongly conserved in the mammalian 
lineage as a type II PDZ binding motif, 
characterized by hydrophobic residues at 
positions –2 and 0 (X-Φ-2-X-1-Φ0-COOH). The 
hydrophobic tail of SPTLC1 is unique compared 
to the C-termini of SPTLC2 and 3, which did not 
conform to any know PDZ binding motifs (data 
not shown). Next, the capacity of SPTLC1 to 
bind PDZ domains was assessed by probing a 
series of protein arrays spotted in duplicate with 
123 PDZ domains from 73 proteins with a 
biotinylated 20-mer SPTLC1 C-terminal peptide. 
Shown are the two arrays containing PDZ 
domains that bound the SPTLC1 peptide (Fig. 
1B). That the binding of the SPTLC1 peptide to 
these domains was driven by a type II interaction 
was indicated by probing additional arrays with a 
peptide (KIAA0316) containing a type I motif, 
characterized by a serine or threonine at the –2 
position (X-S/T-2-X-1-Φ0-COOH), which bound a 
distinct set of PDZ domains compared to the 
SPTLC1 peptide (Fig. 1B). Of the domains that 
the SPTLC1 peptide bound, the most intense 
signal was generated by the single PDZ domain 
from a poorly characterized protein (FRMPD4), 
followed by the signal from the 3rd PDZ domain 
of Par3 (PARD3), a protein that functions to 
establish polarized membrane domains and to 
control directional cell migration (21-25). The 
3rd domain of PTPN13, a protein tyrosine 
phosphatase that regulates cell growth, 
differentiation and oncogenic transformation 
was also found to weakly interact with the 
SPTLC1 peptide (33,34).  
 SPTLC1 mRNA has a reported wide 
tissue distribution, and the Par3 mRNA 
distribution was also found to be more widely 
distributed compared to that of FRMPD4, which 
was principally expressed in the brain and the 
heart (Supplemental Fig 1A). At the protein 
level, expression of Par3 and SPTLC1 was also 
found to be widespread and largely coincident 
(Supplemental Fig 1B). Given the more 
ubiquitous expression of Par3 and the 
involvement of Par3 in establishing polarized 
cell behavior, which also has been shown to 
require sphingolipids and SPT activity (35,36), 
we further investigated the interaction of Par3 
and SPTLC1. Significance of the interaction of 
the SPTLC1 peptide with FRMPD4 and 
PTPN13 PDZ domains detected in our protein 
array screen remains to be investigated and will 
be reported elsewhere. For Par3, we used 
overlay assays to test whether the full-length 
Par3 could interact with SPTLC1, and if so 
whether binding required the SPTLC1 C-
terminal PDZ motif. Purified bacterial 
polypeptides encoding the wild type SPTLC1 C-
terminus or mutant SPTLC1 polypeptides with a 
disrupted PDZ motif (Δ3, VLL-AAA) were 
subjected to SDS-PAGE, transferred to 
nitrocellulose and a 293-EBNA-T cell lysate 
containing HA-tagged Par3 (150 kDa isoform) 
was incubated with the membranes. We found 
Par3 strongly bound the wild type SPTLC1 C-
terminus and that this binding required the type 
II PDZ motif (Fig. 1C). Coomassie stained gels 
run in parallel showed similar amounts of the 
SPTLC1 proteins were used in theses assays, 
which demonstrated that the lack of Par3 
binding to the mutant peptides was not explained 
by loading artifacts. However, because the 
mutant SPTLC1 peptides (particularly the Δ3 
construct) ran anomalously despite being 
reduced and denatured, we conducted further 
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assays where both full-length SPTLC1 and Par3 
were expressed in 293HEK cells and their 
interaction was assessed by immunoprecipition. 
To conduct these experiments, we generated a 
series of SPTLC1 constructs containing either a 
N-terminal FLAG (FL) or Haemagglutin (HA) 
tag, a position that has been previously found to 
preserve SPTLC1 protein interactions and SPT 
activity (7,11). We confirmed these results by 
showing our FL and HA-SPTLC1 constructs, like 
wt-SPTLC1, bind SPTLC2 stabilizing its 
expression and stimulate SPT activity in LY-B 
cells, which lack endogenous SPTLC1 expression 
(Supplemental Fig. 2A & B). Having established 
the utility of our constructs we generated a series 
of mutants that again disrupted the C-terminal 
PDZ motif. Interestingly, either deletion or 
substitution to alanines of the three residues that 
make up the PDZ motif produced mutants that 
expressed substantially less SPTLC1 protein but 
not mRNA suggesting that these sequences are 
important for maintaining SPTLC1 protein 
stability (Fig 2A and Supplemental Fig 3A). But 
the lower expression of these mutants made 
comparison of their ability of bind Par3 difficult. 
Thus, additional mutants were constructed which 
selectively replaced the –2 and 0 positions with 
alanines (SPTLC1-ALA, -VLA and -ALL), 
substitutions that produced mutants which were 
expressed at levels more comparable to wt 
SPTLC1 (Supplemental Fig. 3A). Using the AAA 
and ALA mutants, as well as a third mutant 
(VAA), we tested by immunoprecipitation assays 
whether their interaction with Par3 was disrupted. 
Whereas Par3 co-immunoprecipitated wild type 
SPTLC1, little, if any, mutant SPTLC1 protein 
associated with Par3 (Fig. 2A, IP, top panel). 
Failure of the mutants to interact was not 
explained by the amount of Par3 precipitated in 
these assays since as much or more Par3 was 
present in the precipitates derived from the 
lysates expressing mutant SPTLC1 (Fig. 2A, IP, 
bottom panel). Furthermore, low expression of 
the ALA and VAA mutants could not explain 
their failure to interact with Par3 since total 
expression of these mutants was near that of wt 
SPTLC1 in these assays (Fig. 2A, total lysate, top 
panel). These results were confirmed in converse 
immunoprecipitations where the FL-SPTLC1 
proteins were captured with limiting amounts of 
anti-FLAG antibody beads and eluted with a 
FLAG peptide. Again, mutation of the SPTLC1 
C-terminus disrupted the ability of SPTLC1 to 
co-precipitate Par3, despite similar levels of the 
SPTLC1 mutants being captured by the anti-
FLAG beads and similar levels of Par3 being co-
expressed with the SPTLC1 mutants (Fig. 2B). 
These results indicate that Par3 interacts with 
SPTLC1 in a cellular context and that their 
binding requires the SPTLC1 C-terminal PDZ 
motif.  
Having demonstrated the ability of 
SPTLC1 and Par3 to interact in a cellular setting 
we tested whether the complex could be detected 
at endogenous expression levels in a physiologic 
context. We investigated the expression of Par3 
in the liver, a tissue where SPTLC1 and SPT 
activity are important for the incorporation of 
sphingolipids into lipoproteins and where SPT 
activity is post-translationally regulated by 
ApoE expression (19). Immunoblots of mouse 
liver detected Par3 as a series of isoforms 
ranging from approximately 100 to 150 kDa as 
has been described for Par3 expression in other 
tissues, and as expected the liver expressed 
significant amounts of SPTLC1 and SPTLC2 
(Fig. 2C, left panels). Initially, 
immunoprecipitations were attempted with the 
commercially available Par3 antibody and the 
liver lysates. However, a high level of binding of 
the secondary antibody to the 50 kDa heavy 
chain of the precipitating antibody obscured 
detection of SPTLC1, which is also 50 kDa in 
size. To circumvent this problem additional 
assays were conducted using an SPTLC1 
antibody to precipitate the liver lysates, and it 
was found that the 150 kDa Par3 isoform 
prominently co-precipitated with SPTLC1 (Fig. 
2C, right top panel). This result indicates Par3 
and SPTLC1 can interact at endogenous 
expression levels in the physiologic setting of 
the liver. Since the SPT holoenzyme is formed 
by a complex between SPTLC1 and SPTLC2 we 
also sought to test whether Par3 would also be 
co-precipitated using a SPTLC2 antibody, which 
was found to be the case (Fig. 2C, right bottom 
panel). This result suggested Par3 could either 
directly interact with SPTLC2, or that it was 
associating with the SPT holoenzyme by binding 
the SPTLC1 C-terminal PDZ motif.  
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Par3 can bind the SPTLC1 C-terminus when 
SPTLC1 is associated with SPTLC2 but the 
SPTLC1 PDZ motif is not required for 
holoenzyme formation: Our data indicated that in 
the liver Par3 was able to interact with both 
SPTLC1 and SPTLC2, thus we sought to 
distinguish if this was due an ability to bind the 
SPTLC1 C-terminal PDZ motif in the context of 
SPT holoenzyme, or whether Par3 could also 
directly interact with SPTLC2. To address this 
question we conducted additional 
immunoprecipitation assays using a N-terminal 
Myc-tagged SPTLC2 construct that we verified 
could interact with SPTLC1 in normal manner 
and catalyzed SPT activity, as has been 
previously reported (Supplemental Fig. 2B). 
Myc-SPTLC2 was expressed in 293-EBNA-T 
cells alone, in the presence of Par3, or in the 
presence of Par3 and either SPTLC1 or the 
SPTLC1-ALA mutant. Myc-SPTLC2 was 
precipitated out of lysates from the transfected 
cells, and probing these precipitates detected the 
presence of Par3 in the lysates of cells that 
expressed wt SPTLC1 but not in the lysates of 
cells expressing the SPTLC1-ALA mutant, or in 
lysates of cells expressing only SPTLC2 (Fig. 3, 
top left panel). Probing the blot for SPTLC2 
showed similar amounts Myc-SPTLC2 was 
precipitated out of each of the lysates from the 
Myc-SPTLC2 transfected cells (Fig. 3, bottom 
left panel). Thus, the lack of Par3 in the 
precipitates from the cells expressing the ALA 
mutant was not explained by a failure to 
precipitate Myc-SPTLC2. Likewise, probing for 
the amount of SPTLC1 and SPTLC1-ALA that 
co-precipitated with SPTLC2 indicated SPTLC2 
still captured a significant amount of the 
SPTLC1-ALA mutant (Fig. 3, middle left panel). 
Finally, probing for the total amount of Par3 in 
the cell lysates used to perform these 
immunoprecipitations showed it was expressed at 
similar levels when expressed in the presence of 
SPTLC2 alone or in the presence of SPTLC1 and 
the ALA mutant (Fig 3 top right panel). These 
results indicate SPTLC2 alone is not able interact 
with Par3, but that in the presence of SPTLC1 
carrying an intact C-terminal PDZ motif SPTLC2 
can co-precipitate Par3.  
However, since Myc-SPTLC2 was able 
to still co-precipitate SPTLC1-ALA this indicates 
the association of SPTLC1 and SPTLC2 does not 
have a critical dependence upon the SPTLC1 
PDZ motif. To further verify that the SPTLC1 
PDZ motif mutants could bind SPTLC2 we 
conducted additional co-expression studies and 
quantitated the ability of SPTLC1 and the 
SPTLC1-AAA and ALA mutants to stabilize 
SPTLC2 protein expression. Again, when the 
amount SPTLC2 protein expression was 
normalized to the amount of expressed wt or 
mutant SPTLC1 protein, the mutants showed 
little or no deficit in their ability to stabilize 
SPTLC2 protein expression confirming that they 
are expressed as normally folded proteins 
capable of binding and stabilizing SPTLC2 
(Supplemental Fig. 3C). In aggregate, these 
results indicate Par3 can interact with the 
SPTLC1/2 holoenzyme at physiologic 
expression levels in the liver and that the 
association of Par3 with the holoenzyme is 
mediated by its ability to bind the SPTLC1 PDZ 
motif.  
 
Par3 modulates THP-1 monocyte SPT activity 
and ceramide levels: Given Par3 interacted with 
the SPTLC1/2 holoenzyme we sought to test 
whether Par3 could influence SPT activity. As in 
the liver, SPTLC1 is also expressed in cells of 
the monocyte-macrophage lineage, a cell type 
whose migration to the subendothelial space of 
inflamed coronary arteries plays a key role in the 
development of atherosclerosis (37). Moreover, 
since both Par3 and sphingolipids have been 
implicated in polarized cell behavior we tested 
whether Par3 was expressed in the monocyte-
macrophage cell lineage, and if so whether Par3 
influenced SPTLC1 expression and function. To 
address this possibility we probed for Par3 
expression in human THP-1 monocyte-
macrophages and found these cells do express 
Par3 protein as undifferentiated monocytes, as 
well as when differentiated to the adherent 
macrophage phenotype induced by the phorbol 
ester PMA (Fig. 4A & Supplemental Fig. 4A). 
Likewise, primary mouse bone marrow 
macrophages also were found to express Par3 
and immuno-precipitation of the SPT 
holoenzyme using either SPTLC1 or SPTLC2 
antibodies co-precipitated Par3 (Supplemental 
Fig. 4B). These results indicate Par3 is 
expressed in cells of the monocyte-macrophage 
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lineage and can associate with the SPT 
holoenyzme.  
To test whether Par3 influences SPTLC1 
function, lentiviral vectors were used to introduce 
shRNAs into THP-1 cells that suppress Par3 
mRNA expression. Compared to THP-1 
monocytes infected with a control lentivirus 
expressing a shRNA targeting GFP, cells 
expressing shRNAs targeting Par3 mRNA 
showed a pronounced decrease in Par3 protein 
expression (Fig. 4A, top panel). Similarly, in cells 
expressing a shRNA targeting SPTLC1, protein 
levels of SPTLC1 were markedly depleted (Fig. 
4A, second panel). Probing this blot for SPTLC2 
showed lower SPTLC2 protein levels in the 
lysate from cells expressing the SPTLC1 shRNA, 
as well as in the lysates from cells expressing the 
F12 Par3 shRNA (Fig. 4A, third panel). 
However, after normalization to β-actin in a 
series of blots it was found that loss of Par3 did 
not have a significant impact on expression levels 
of either SPTLC1 or SPTLC2 (Supplemental Fig. 
4C). Likewise, knockdown of SPTLC1 did not 
significantly alter Par3 protein levels, but did 
reduce levels of SPTLC2 as has been previously 
reported (Supplemental Fig. 4C). These results 
indicate Par3 expression is not critical for 
maintaining SPTLC1 protein stability and suggest 
the poor expression observed for the SPTLC1-Δ3 
and AAA mutants is likely not accounted for by 
an inability to bind Par3 in 293 cells. 
Having established THP-1 cells that 
stably suppress Par3 or SPTLC1 protein 
expression we next quantitated levels of SPT 
activity in lysates from these cells. Compared to 
lysates from the cells expressing the GFP 
shRNA, lysates from cells expressing shRNAs 
against Par3 or SPTLC1 had significant 
reductions in SPT activity of approximately 40% 
and 50%, respectively (Fig. 4B). This was an 
intermediate level of inhibition compared to that 
induced by treating the cells with the SPT 
inhibitor myriocin (10 μM), which inhibited 
activity by approximately 90%. To rule out that 
the lost of SPT activity in the Par3 or SPTLC1 
lysates was due to a general inhibitory effect on 
cell viability or metabolism we measured the cell 
line’s ATP levels and their ability to metabolize 
tetrazolium salts as a measure of mitochondria 
function, finding no significant differences in 
these parameters (Supplemental Fig. 4D). 
Additionally, because our results suggest Par3 
binding to SPTLC1 may act to recruit the SPT 
holoenzyme to Par3 associated microdomains 
we further tested whether such an effect may 
alter the amount of SPTLC1 that partitions into 
the microsomal membranes derived from Par3 
suppressed THP1 cells and thus could explain 
the lost of SPT activity seen in these lysates, but 
this was not found to be the case since SPT 
activity when normalized to SPTLC1 contained 
in the microsomal fraction was still found to be 
significantly reduced (supplemental Fig. 5A).  
Having confirmed all the cell lines were 
equally viable, we next used 14C-serine to assess 
whether Par3 modulated de-novo synthesis of 
sphingolipids that are generated by SPTLC1 and 
SPT activity. Here, THP-1 cells expressing the 
Par3 or SPTLC1 shRNAs were compared to 
either un-infected THP-1 cells or THP-1 cells 
expressing the shRNA targeting GFP. Equal 
numbers of cells (5 X 106) were incubated in 
media containing 5 μCi of 14C-serine, and to 
control for lipids whose synthesis depended 
upon SPT activity additional cells expressing the 
GFP shRNA were preincubated for 2 h with 10 
μM myriocin to block SPT activity. Then after 
24 h of additional incubation at 37°C, 14C-serine 
labeled lipids were extracted from the cells with 
chloroform/methanol and separated on TLC 
plates along with purified standards for 
ceramide, sphingomyelin and 
phosphatidylserine. Phosphor images of labeled 
ceramide, sphingomyelin and phosphatidylserine 
are shown in Fig. 4C. As was found in the cell 
free assays, knockdown of either SPTLC1 or 
Par3 reduced the de novo synthesis of ceramide 
and sphingomyelin but had little effect on the 
level of incorporation of 14C-serine into 
phosphatidylserine. And like the effect of the 
SPTLC1 and Par3 siRNAs, myriocin treatment 
of the control cells expressing the GFP siRNA 
strongly reduced incorporation of 14C-serine into 
ceramide and sphingomyelin but not 
phosphatidylserine (Fig. 4C, right panels). 
Quantification of the Par3 siRNA effect showed 
a significant approximately 40% decrease in the 
de novo synthesis of sphingomyelin and 
ceramide (Supplemental Fig 5B). Thus, as 
analyzed by both cell free assays for SPT 
activity and by 14C-serine labeling of de novo 
synthesized sphingolipids loss of Par3 
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expression in THP-1 cells inhibited the activity of 
the SPTLC1/2 holoenzyme.  
 
Par3 and SPTLC1 are required for MCP-1 
induced chemotaxis of THP-1 monocytes: Given 
Par3 modulated THP-1 monocyte SPT activity 
and sphingolipid synthesis we further tested if 
Par3 and SPTLC1 may influence the migratory 
behavior of these cells. Because Par3 has been 
recently shown to be required for polarized 
migration of keratinocytes and since inhibition of 
SPT activity has also been shown to inhibit 
neuronal cell migration (25,36), we speculated 
that Par3 and SPTLC1 could play a role in the 
ability of monocytes to migrate towards an 
inflammatory signal. To explore this possibility 
we tested whether lost of either Par3 or SPTLC1 
expression in THP-1 monocytes inhibited the 
ability of these cells to migrate toward a gradient 
of monocyte chemoattractant protein 1 (MCP-1) 
using the Boyden-chamber assay. Compared to 
control cells expressing the shRNA directed 
against GFP, cells expressing either shRNAs 
targeting Par3 or SPTLC1 had a significant 50% 
reduction in their ability to migrate in response to 
the MCP-1 signal (Fig. 5A). As indicated above 
this inhibition of migration was not accounted for 
by a difference in viability as determined by 
MTT assays and by measurement of ATP 
production in these cells (Supplemental Fig. 4D). 
Furthermore, the defect imparted by loss of Par3 
or SPTLC1 was specific for the polarized 
response to MCP1 since the number of cells that 
randomly migrated into the lower chamber in the 
absence of the chemokine was similar for all the 
cell lines (Supplemental Fig. 5C). To test whether 
the defect in MCP-1 induced migration seen in 
the cells with suppressed Par3 expression was 
acting through a mechanism that involved the 
ability of Par3 to modulate SPT activity, control 
and Par3 knockdown cells were first pretreated 
for 24 h with vehicle or myriocin to inhibit SPT. 
Then the ability of the cells to migrate in 
response to MCP-1 was again tested. As before, 
the MCP-1 induced migration of the cells 
expressing the Par3 shRNA was reduced by over 
60% compared to the control cells expressing the 
GFP shRNA (Fig. 5B). Additionally, 
pretreatment of the control GFP shRNA 
expressing cells with myriocin inhibited MCP-1 
induced migration by approximately 40%, but 
myriocin pretreatment did not further affect the 
residual MCP-1 induced migration of cells with 
suppressed Par3 expression (Fig. 5B). This 
result suggested the ability of myriocin to 
modulate migration in response to MCP-1 was 
acting through a mechanism that depends upon 
the expression of Par3. Because the cells with 
suppressed Par3 expression were found to have a 
defect in the de novo synthesis of ceramide, and 
because ceramide has previously been reported 
to be important in the induction of neuronal cell 
migration (36), we tested whether supplying 
exogenous ceramide to cells with suppressed 
Par3 expression improved their response to 
MCP-1. This was found to be the case in that 
ceramide treatment of Par3 suppressed cells 
significantly improved their migratory response 
to MCP-1 (Fig. 5C). In composite this data 
indicates Par3 modulated THP-1 migration 
through a mechanism that depended upon SPT 
activity and likely the de novo synthesis of 
ceramide. However, since ceramide treatment 
did not completely restore the migration defect 
of the Par3 suppressed cells it is possibly that the 
synthesis of sphingomyelin or other bioactive 
lipids may also be involved.  
To explore whether THP-1 monocytes 
more broadly require Par3 and SPTLC1 to 
respond to inflammatory stimuli we measured 
the ability of the Par3 and SPTLC1 shRNA 
suppressed cells to respond to fractalkine and 
fMLP. Fractalkine is a CX3C chemokine, a class 
distinct from MCP-1, but like MCP-1, 
fractalkine is also important for recruiting 
monocytes to sites of vascular inflammation and 
has also been found to be pro-atherosclerotic 
(38,39). fMLP is a formylated tripeptide 
released by bacteria at sites of infection that like 
MCP-1 and fractalkine induces chemotaxis by 
signaling through G-protein coupled receptors 
(40). As with MCP-1, the response of the cells 
with suppressed Par3 or SPTLC1 expression 
showed significant deficits in their ability to 
migrate towards a gradient of fractalkine or 
fMLP-1, although the response of SPTLC1 
targeted cells towards fMLP-1 was found to be 
more variable (Fig. 6A & B). In composite our 
results indicate Par3 and SPTLC1 are broadly 
required for the ability of THP-1 monocytes to 
respond to a number of inflammatory signals.  
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DISSCUSSION 
Here we have identified a protein-protein 
interaction between SPTLC1 and Par3, a PDZ 
protein. In mammals the SPTLC1 C-terminus has 
been conserved as a type II PDZ binding motif, 
and our array screen showed a C-terminal 
SPTLC1 peptide bound the 3rd PDZ domain of 
Par3. Overlay assays confirmed the 150 kDa 
isoform of Par3 interacts with the SPTLC1 C-
terminus and that this binding required the 
SPTLC1 PDZ motif. Immunoprecipitation assays 
show Par3 is able to form a complex with the 
SPTLC1/2 holoenzyme by binding the SPTLC1 
PDZ motif, and we found Par3 interacted with the 
holoenzyme at endogenous expression levels in 
the liver and in primary macrophages. Par3 is 
expressed in both human THP-1 monocytes and 
macrophages and shRNA suppression of Par3 in 
THP-1 monocytes was found to inhibit 
holoenzyme serine palmitoyltransferase activity 
and de novo sphingolipid synthesis. Par3 or 
SPTLC1 shRNA suppression also significantly 
impaired polarized THP-1 monocyte migration in 
response to gradients of inflammatory 
chemokines but did not alter cell viability or 
random migration. Likewise, pharmacologic 
inhibition of the SPT holoenzyme modulated 
MCP-1 induced migration through a mechanism 
that depended upon Par3 expression, and 
ceramide treatment significantly improved the 
Par3 defect in migration. These results have 
uncovered a novel physical and functional link 
between SPTLC1 and Par3 that is associated with 
increased SPT activity and polarized migration 
towards an inflammatory signal.  
 Our work provides new insight into the 
role that Par3 protein-protein interactions play in 
controlling polarized migration towards a 
chemotactic signal. Recently, the migration of 
keratinocytes induced by epidermal growth factor 
has also been shown to depend upon Par3 (25). 
And like for the more established role of Par3 in 
mediating tight junction formation that delineates 
apical/basolateral polarity of epidermal tissues, 
this regulation of keratinocyte migration is 
characterized by the Par3 recruitment of atypical 
PKC to membrane microdomains. Atypical PKC 
recruitment is of interest since migration of 
neuronal precursor cells and establishment of 
polarity in the primitive ectoderm have also been 
found to depend on de novo synthesis of 
ceramide and the recruitment of atypical PKC to 
ceramide rich membrane microdomains (35,36). 
Our work extends these observations by 
showing Par3 and SPTLC1 modulate the 
migratory response of cells of the monocyte 
lineage to gradients of inflammatory 
chemokines. In addition to MCP-1, we found the 
ability of THP-1 monocytes to respond to other 
chemokines including fractalkine and fMLP also 
had a dependence upon Par3 and SPTLC1. 
Because the Par3 polarity complex has recently 
been shown to be required for T-cell polarization 
and migration towards stromal cell-derived 
factor-1 α (21), another chemokine that triggers 
G-protein coupled signaling, these and our 
observations indicate Par3 plays a broad role in 
mediating chemokine induced polarized 
migration of immune cells. Assuming SPTLC1 
also plays a similarly broad role in mediating the 
migratory responses to inflammatory signals, 
our results may provide mechanistic explanation 
for studies that have associated the ability of the 
SPT inhibitor myriocin to reduce atherosclerosis 
in ApoE-/- mice with an ability to reduce the 
macrophage content of their atherosclerotic 
lesions (41).  
 What is the relationship between the 
binding of Par3 and SPTLC1 and the ability of 
Par3 to stimulate SPT activity and monocyte 
migration? Although deleting or mutating the 
SPTLC1 C-terminal PDZ motif to alanines was 
found to destabilize SPTLC1 protein expression, 
more subtle substitutions of this motif that 
disrupted the ability of Par3 to bind SPTLC1 did 
not have a strong effect on the stability of 
SPTLC1. This suggests the binding of SPTLC1 
by Par3 does not play a critical role in stabilizing 
SPTLC1 protein expression, a result further 
confirmed by SPTLC1 protein levels not being 
significantly altered in THP-1 cells expressing 
Par3 targeted shRNAs. SPTLC2 expression in 
the Par3 suppressed cells was also similar to that 
of control cells, and it was found that the 
mutation of the SPTLC1 PDZ motif did not 
prevent the SPTLC1 binding and stabilization of 
SPTLC2. Because a third SPT subunit has been 
identified, it is possible that Par3 could modulate 
the interaction of SPTLC1 with this subunit (8). 
However, this seems unlikely to explain the 
ability of Par3 to modulate SPT activity in THP-
1 monocytes since we were unable to detect 
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SPTLC3 expression in these cells (unpublished 
observations N. Tamehiro, ML Fitzgerald). In 
aggregate, our results indicate the SPTLC1 PDZ 
motif and Par3 binding of this motif do not play a 
critical role in the ability of SPTLC1 to bind and 
stabilize SPTLC2.  
Since Par3 modulated SPT activity but 
did not alter the protein levels of SPTLC1 and 2, 
and since Par3 is known to recruit and activate 
atypical PKC, it is possible that Par3 may be 
modulating the phosphorylation status of the SPT 
holoenzyme. This possibility is intriguing since a 
number a reports have suggested SPT activity is 
regulate at the post-translational level (19,42,43), 
and analysis of SPTLC1 and 2 orthologs indicate 
both have well conserved potential 
phosphorylation sites. Additionally, the migration 
of SPTLC2 on 2D gels is altered by phosphatase 
treatment suggesting it is indeed a 
phosphoprotein (T Hornemann unpublished 
observations). In such a model the Par 3 binding 
of the SPTLC1 PDZ motif may be a mechanism 
to alter the phosphorylation status of the SPT 
holoenzyme as means to modulate the de novo 
synthesis of sphingolipids, possibly in response to 
an inflammatory stimulus. Whether this could 
occur in polarized microdomains organized by 
Par3 remains to be clarified, although our co-
expression studies suggests this may be the case 
in that when expressed in the presence of Par3 
SPLTC1 was found to co-localize with Par3 in 
the cell periphery near sites of cell-cell contact 
and in cellular protrusions (unpublished 
observations N. Tamehiro, ML Fitzgerald). 
These results suggest Par3 may be able to 
dynamically alter the distribution of SPTLC1 
and give insight into a recent report by Wei et al 
that suggests SPTLC1 can associated with focal 
adhesion complexes in the cell periphery (44). In 
summary, we have identified a protein 
interaction between Par3 and SPTLC1 that is 
associated with increased serine 
palmitoyltransferase activity and migration of 
THP-1 monocytes towards a number of 
inflammatory chemokines. And although the 
mechanism of this association needs to be 
clarified the results lend additional support for a 
model in which SPTLC1 acts as a regulator of 
SPT activity by interacting with Par3 and other 
proteins such as ABCA1 in order to couple 
signals that integrate cellular demand for the de 
novo synthesis of sphingolipids with the 
biogenesis of membrane lipid domains (20). 
Further investigation of this hypothesis is 
warranted, particularly since additional small 
subunits of the SPT holoenzyme have been 
recently identified by Han et al that alter acyl-
CoA substrate specificity and appear to be 
required for maximal enzyme activity (45).  
  
REFERNECES 
 
1. Rivera, J., Proia, R. L., and Olivera, A. (2008) Nat Rev Immunol 8, 753-763 
2. van Meer, G., Voelker, D. R., and Feigenson, G. W. (2008) Nat Rev Mol Cell Biol 
9, 112-124 
3. Wymann, M. P., and Schneiter, R. (2008) Nat Rev Mol Cell Biol 9, 162-176 
4. Zuo, Y., Zhuang, D. Z., Han, R., Isaac, G., Tobin, J. J., McKee, M., Welti, R., 
Brissette, J. L., Fitzgerald, M. L., and Freeman, M. W. (2008) J Biol Chem 283, 
36624-36635 
5. Hanada, K. (2003) Biochim Biophys Acta 1632, 16-30 
6. Hanada, K., Hara, T., Fukasawa, M., Yamaji, A., Umeda, M., and Nishijima, M. 
(1998) J Biol Chem 273, 33787-33794 
7. Hanada, K., Hara, T., and Nishijima, M. (2000) J Biol Chem 275, 8409-8415 
8. Hornemann, T., Richard, S., Rutti, M. F., Wei, Y., and von Eckardstein, A. (2006) 
J Biol Chem 281, 37275-37281 
9. Hornemann, T., Wei, Y., and von Eckardstein, A. (2007) Biochem J  
10. Mandon, E. C., Ehses, I., Rother, J., van Echten, G., and Sandhoff, K. (1992) J 
Biol Chem 267, 11144-11148 
11. Yasuda, S., Nishijima, M., and Hanada, K. (2003) J Biol Chem 278, 4176-4183 
 11
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 5, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
12. Jiang, X. C., Paultre, F., Pearson, T. A., Reed, R. G., Francis, C. K., Lin, M., 
Berglund, L., and Tall, A. R. (2000) Arterioscler Thromb Vasc Biol 20, 2614-
2618 
13. Nelson, J. C., Jiang, X. C., Tabas, I., Tall, A., and Shea, S. (2006) Am J Epidemiol 
163, 903-912 
14. Glaros, E. N., Kim, W. S., Quinn, C. M., Jessup, W., Rye, K. A., and Garner, B. 
(2007) J Lipid Res  
15. Glaros, E. N., Kim, W. S., Wu, B. J., Suarna, C., Quinn, C. M., Rye, K. A., 
Stocker, R., Jessup, W., and Garner, B. (2007) Biochem Pharmacol 73, 1340-
1346 
16. Hojjati, M. R., Li, Z., Zhou, H., Tang, S., Huan, C., Ooi, E., Lu, S., and Jiang, X. 
C. (2005) J Biol Chem 280, 10284-10289 
17. Park, T. S., Panek, R. L., Mueller, S. B., Hanselman, J. C., Rosebury, W. S., 
Robertson, A. W., Kindt, E. K., Homan, R., Karathanasis, S. K., and Rekhter, M. 
D. (2004) Circulation 110, 3465-3471 
18. Park, T. S., Panek, R. L., Rekhter, M. D., Mueller, S. B., Rosebury, W. S., 
Robertson, A., Hanselman, J. C., Kindt, E., Homan, R., and Karathanasis, S. K. 
(2006) Atherosclerosis 189, 264-272 
19. Jeong, T., Schissel, S. L., Tabas, I., Pownall, H. J., Tall, A. R., and Jiang, X. 
(1998) J Clin Invest 101, 905-912 
20. Tamehiro, N., Zhou, S., Okuhira, K., Benita, Y., Brown, C. E., Zhuang, D. Z., 
Latz, E., Hornemann, T., von Eckardstein, A., Xavier, R. J., Freeman, M. W., and 
Fitzgerald, M. L. (2008) Biochemistry 47, 6138-6147 
21. Gerard, A., Mertens, A. E., van der Kammen, R. A., and Collard, J. G. (2007) J 
Cell Biol 176, 863-875 
22. Joberty, G., Petersen, C., Gao, L., and Macara, I. G. (2000) Nat Cell Biol 2, 531-
539 
23. Lin, D., Edwards, A. S., Fawcett, J. P., Mbamalu, G., Scott, J. D., and Pawson, T. 
(2000) Nat Cell Biol 2, 540-547 
24. Nishimura, T., and Kaibuchi, K. (2007) Dev Cell 13, 15-28 
25. Pegtel, D. M., Ellenbroek, S. I., Mertens, A. E., van der Kammen, R. A., de Rooij, 
J., and Collard, J. G. (2007) Curr Biol 17, 1623-1634 
26. Hubbard, T. J., Aken, B. L., Ayling, S., Ballester, B., Beal, K., Bragin, E., Brent, 
S., Chen, Y., Clapham, P., Clarke, L., Coates, G., Fairley, S., Fitzgerald, S., 
Fernandez-Banet, J., Gordon, L., Graf, S., Haider, S., Hammond, M., Holland, R., 
Howe, K., Jenkinson, A., Johnson, N., Kahari, A., Keefe, D., Keenan, S., 
Kinsella, R., Kokocinski, F., Kulesha, E., Lawson, D., Longden, I., Megy, K., 
Meidl, P., Overduin, B., Parker, A., Pritchard, B., Rios, D., Schuster, M., Slater, 
G., Smedley, D., Spooner, W., Spudich, G., Trevanion, S., Vilella, A., Vogel, J., 
White, S., Wilder, S., Zadissa, A., Birney, E., Cunningham, F., Curwen, V., 
Durbin, R., Fernandez-Suarez, X. M., Herrero, J., Kasprzyk, A., Proctor, G., 
Smith, J., Searle, S., and Flicek, P. (2009) Nucleic Acids Res 37, D690-697 
27. Okuhira, K., Fitzgerald, M. L., Sarracino, D. A., Manning, J. J., Bell, S. A., Goss, 
J. L., and Freeman, M. W. (2005) J Biol Chem 280, 39653-39664 
28. Fitzgerald, M. L., Okuhira, K., Short, G. F., 3rd, Manning, J. J., Bell, S. A., and 
Freeman, M. W. (2004) J Biol Chem 279, 48477-48485 
 12
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 5, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
29. Doering, T., Holleran, W. M., Potratz, A., Vielhaber, G., Elias, P. M., Suzuki, K., 
and Sandhoff, K. (1999) J Biol Chem 274, 11038-11045 
30. Han, G., Gable, K., Yan, L., Natarajan, M., Krishnamurthy, J., Gupta, S. D., 
Borovitskaya, A., Harmon, J. M., and Dunn, T. M. (2004) J Biol Chem 279, 
53707-53716 
31. Chen, J. R., Chang, B. H., Allen, J. E., Stiffler, M. A., and MacBeath, G. (2008) 
Nat Biotechnol 26, 1041-1045 
32. Stiffler, M. A., Chen, J. R., Grantcharova, V. P., Lei, Y., Fuchs, D., Allen, J. E., 
Zaslavskaia, L. A., and MacBeath, G. (2007) Science 317, 364-369 
33. Sato, T., Irie, S., Kitada, S., and Reed, J. C. (1995) Science 268, 411-415 
34. Zhu, J. H., Chen, R., Yi, W., Cantin, G. T., Fearns, C., Yang, Y., Yates, J. R., 3rd, 
and Lee, J. D. (2008) Oncogene 27, 2525-2531 
35. Krishnamurthy, K., Wang, G., Silva, J., Condie, B. G., and Bieberich, E. (2007) J 
Biol Chem 282, 3379-3390 
36. Wang, G., Krishnamurthy, K., Chiang, Y. W., Dasgupta, S., and Bieberich, E. 
(2008) J Neurochem 106, 718-733 
37. Park, Y. M., Febbraio, M., and Silverstein, R. L. (2009) J Clin Invest 119, 136-
145 
38. Boring, L., Gosling, J., Cleary, M., and Charo, I. F. (1998) Nature 394, 894-897 
39. Lesnik, P., Haskell, C. A., and Charo, I. F. (2003) J Clin Invest 111, 333-340 
40. Stevenson, N. J., Haan, S., McClurg, A. E., McGrattan, M. J., Armstrong, M. A., 
Heinrich, P. C., and Johnston, J. A. (2004) J Immunol 173, 3243-3249 
41. Park, T. S., Rosebury, W., Kindt, E. K., Kowala, M. C., and Panek, R. L. (2008) 
Pharmacol Res 58, 45-51 
42. Herget, T., Esdar, C., Oehrlein, S. A., Heinrich, M., Schutze, S., Maelicke, A., 
and van Echten-Deckert, G. (2000) J Biol Chem 275, 30344-30354 
43. Perry, D. K., Carton, J., Shah, A. K., Meredith, F., Uhlinger, D. J., and Hannun, 
Y. A. (2000) J Biol Chem 275, 9078-9084 
44. Wei, J., Yerokun, T., Leipelt, M., Haynes, C. A., Radhakrishna, H., Momin, A., 
Kelly, S., Park, H., Wang, E., Carton, J. M., Uhlinger, D. J., and Merrill, A. H., Jr. 
(2009) Biochim Biophys Acta In Press.  
45. Han, G., Gupta, S., Gable, K., Niranjanakumari, S., Moitra, P., Eichler, F., 
Brown, R., Harmon, J., and Dunn, T. (2009) Proceedings of the National 
Academy of Sciences of the United States of America 106, 8186-8191 
 
 
Footnotes 
*This work was supported by NIH-NHLBI and American Heart Association grants to ML 
Fitzgerald (HL074136, 09GRNT2260352) and by fellowship training grants from the Uehara 
Memorial Foundation, the Nagai Foundation of Tokyo and the Japan Heart Foundation (N 
Tamehiro), the American Heart Association (Z Mujawar) and the Massachusetts Biomedical 
Research Corporation (S. Zhou). The authors would also like to acknowledge the technical advice 
provided by the laboratory of Dr. Kathryn J. Moore for the cell migration assays and the helpful 
comments provided by Dr. Mason W. Freeman. 
 
The abbreviations used are: Par3, Partitioning Defective Protein 3; SPT, serine 
palmitoyltransferase; SM, sphingomyelin; Cer, ceramide; PS, phosphatidylserine.  
 13
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 5, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
FIGURE LEDGENDS 
 
Figure1. SPTLC1 contains a conserved C-terminal PDZ motif that interacts with the 3rd 
PDZ domain of Par3. A, An alignment of the C-terminal 25 amino acids of SPTLC1 from the 
indicated species is shown and the final three conserved hydrophobic residues that conform to a 
class II PDZ motif (X-Φ-2-X-1-Φ0-COOH) are boxed. B, The SPTLC1 C-terminus is able to bind 
to the third PDZ domain of Par3 as identified by the binding of a biotinylated 20-mer C-terminal 
SPTLC1 peptide to protein arrays that are spotted in duplicate with 123 PDZ domains from 73 
proteins. Shown in the left panels are the two arrays of four that contained PDZ domains that 
bound the SPTLC1 peptide (signal intensity FRMPD4>Par3>PTPN13). That binding of the 
SPTLC1 peptide to these PDZ domains was driven by a type II interaction was indicated by the 
binding pattern of a control biotinylated peptide (KIAA0316), which conforms to a class I PDZ 
motif (X-S/T-2-X-1-Φ0-COOH) and interacts with a distinct set of PDZ domains (right panels). C, 
The binding of full length Par3 (150 kDa isoform) to the SPTLC1 C-terminus requires the final 
three residues that comprise the SPTLC1 type II PDZ motif as determined by overlay assays. 
Purified bacterial polypeptides encoding the wild type SPTLC1 C-terminus or the C-terminus 
with the PDZ motif deleted (Δ3) or substituted with alanines (AAA) were separated by SDS-
PAGE and transferred to nitrocellulose. Incubation of the membrane with a lysate containing HA 
tagged Par3 expressed in 293-EBNA-T cells only bound wt SPTLC1 as determined by 
immunoblotting with an anti-HA antibody. Gels run in parallel and Coomassie stained for total 
SPTLC1 protein indicate the failure of Par3 to bind the mutant SPTLC1 polypeptides was not due 
to unequal loading in these assays. 
  
Figure 2. Par3 binding of SPTLC1 requires the SPTLC1 Type II PDZ motif and occurs at 
physiologic expression levels in the mouse liver. A, Immuno-precipitation of HA-Par3 out of 
293-EBNA-T cells expressing FLAG (FL) tagged SPTLC1 or the indicated FL-SPTLC1 mutants 
show the SPTLC1 C-terminal PDZ motif is required for the binding of SPTLC1 and Par3 in a 
cellular context. The top two panels show immuno-blots of the precipitated SPTLC1 and Par3, 
and the lower two panels show the amount of total SPTLC1 and Par3 expressed in the transiently 
transfected 293 HEK cells. B, Converse immuno-precipitations of the FL-SPTLC1 proteins 
confirm the Par3 interaction with SPTLC1 requires the SPTLC1 C-terminal PDZ motif. C, The 
Par3 150 kDa isoform is expressed in the mouse liver along with the SPTLC1 and SPTLC2 
subunits as determined by immunoblots (left panels), and interacts with SPTLC1 and SPTLC2 as 
determined by immuno-precipitation of the liver lysates with normal IgG or antibodies against 
SPTLC1 (top right panel) or SPTLC2 (lower right panel).  
 
Figure 3. Par3 interacts with the SPTLC1/2 holoenyzme through an interaction with the 
SPTLC1 PDZ motif. Myc-tagged SPTLC2 was co-transfected into 293-EBNA-T cells alone, or 
in the presence of HA-Par3 and the indicated FL-SPTLC1 constructs. SPTLC2 was immuno-
precipitated with an anti-Myc antibody and the amount of Par3, SPTLC1 and SPTLC2 that 
precipitated was determined by immuno-blotting (left panels), and immuno-blotting the input 
protein lysates shows the total amount of Par3, SPTLC1 and SPTLC2 that was expressed in the 
cells (right panels). 
  
Figure 4. ShRNA suppression of Par3 in human THP-1 monocytes inhibits serine 
palmityoltransferase activity. A, THP-1 monocytes express Par3, SPTLC1 and SPTLC2 as 
determined by immunoblotting, and lentiviral mediate expression of shRNAs targeting Par3 (G1 
& F12) or SPTLC1 specifically repress Par3 and SPTLC1 protein expression, respectively. B, 
Lentiviral delivered shRNAs targeting Par3 and SPTLC1 inhibit serine palmitoyltransferase 
activity (SPT) by approximately 40% in THP-1 monocytes as determined by measuring the 
condensation of C14-serine and palmitoyl-CoA catalyzed by microsomal cell lysates. Pretreatment 
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of the SPTLC1 targeted lysate with the SPT inhibitor myriocin further inhibited activity to 90% 
(B2 + myriocin, n=3, ± SD, * p< 0.05). C. De novo synthesis of ceramide and sphingomyelin is 
reduced in cells expressing shRNAs targeting Par3 or SPTLC1 expression as compared to un-
infected control cells, or cells expressing a lentiviral delivered shRNA targeting GFP. As with the 
Par3 and SPTLC1 targeted cells, myriocin treatment of the control GFP targeted cells reduced 
incorporation of C14-serine into ceramide (Cer) and sphingomyelin (SM) but not 
phosphatidylserine (PS). Cells were incubated with C14-serine (5 μCi) for 24 h at 37°C and 
cellular lipids were isolated by chloroform/methanol extraction and separated on TLC plates 
along with purified standards for Cer, SM and PS. Labeled lipids remaining at the plate origin 
was similar demonstrating equal loading of the samples (results representative of two or more 
independent experiments, and quantification of labeled Cer and SM is shown in Supplemental 
Figure 5B). 
 
Figure. 5 shRNA suppression of Par3 and SPTLC1 inhibits polarized migration of THP-1 
cells in response to monocyte chemoattractant protein 1. A, THP-1 monocytes expressing 
shRNAs against Par3 or SPTLC1 have an approximately 50% reduction in their ability to migrate 
towards a gradient of MCP-1 (10 nM) compared to control cells expressing a shRNA targeting 
GFP as determined by Boyden chamber assays. B, Myriocin pretreatment of control cells 
expressing the GFP shRNA reduces their MCP-1 induced migration by 44% but does affect the 
residual MCP-1 induced migration of THP-1 monocytes with suppressed Par3 expression. C, 
Ceramide pretreatment of Par3 suppressed THP-1 monocytes significantly improves their MCP-1 
induced migration defect (n=3, ± SD, * p< 0.05 vs. shGFP untreated, # p< 0.05 vs shPar3 
untreated, results representative of two or more independent experiments). 
 
Figure 6. Loss of Par3 or SPTLC1 expression inhibits THP-1 chemotaxis induced by 
structurally diverse chemokines including fractalkine and the fMLP bacterial formylated 
tripeptide. A, Fractalkine (10 nM) induced migration of THP-1 cells expressing shRNAs against 
Par3 or SPTLC1 is reduce by approximately 80% compared to control cells expressing a shRNA 
targeting GFP. B, fMLP (10 nM) induced migration of THP-1 cells expressing shRNAs against 
SPTLC1 or Par3 is reduced approximately 60 and 80%, respectively, as compared to the control 
GFP shRNA cells. (n=3, ± SD, * p< 0.05, results are representative of two or more independent 
experiments). 
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